

Kevin M Shannon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9239912/publications.pdf>

Version: 2024-02-01

177
papers

12,856
citations

25031

57
h-index

24978

109
g-index

182
all docs

182
docs citations

182
times ranked

13544
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyperactive Ras in developmental disorders and cancer. <i>Nature Reviews Cancer</i> , 2007, 7, 295-308.	28.4	1,422
2	Germline KRAS mutations cause Noonan syndrome. <i>Nature Genetics</i> , 2006, 38, 331-336.	21.4	670
3	Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. <i>Nature Genetics</i> , 1996, 12, 144-148.	21.4	555
4	Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. <i>Nature Genetics</i> , 2008, 40, 600-608.	21.4	514
5	Loss of The Normal NF1 Allele from the Bone Marrow of Children with Type 1 Neurofibromatosis and Malignant Myeloid Disorders. <i>New England Journal of Medicine</i> , 1994, 330, 597-601.	27.0	423
6	Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. <i>Blood</i> , 2004, 103, 2325-2331.	1.4	415
7	Homozygous Inactivation of the NF1 Gene in Bone Marrow Cells from Children with Neurofibromatosis Type 1 and Malignant Myeloid Disorders. <i>New England Journal of Medicine</i> , 1997, 336, 1713-1720.	27.0	285
8	Somatic activation of oncogenic <i>Kras</i> in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 597-602.	7.1	279
9	MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2014, 25, 652-665.	16.8	274
10	Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. <i>Blood</i> , 2009, 114, 1859-1863.	1.4	260
11	Outcomes in CCG-2961, a Children's Oncology Group Phase 3 Trial for untreated pediatric acute myeloid leukemia: a report from the Children's Oncology Group. <i>Blood</i> , 2008, 111, 1044-1053.	1.4	259
12	Myelodysplastic and Myeloproliferative Disorders of Childhood: A Study of 167 Patients. <i>Blood</i> , 1999, 93, 459-466.	1.4	221
13	Single-Cell Profiling Identifies Aberrant STAT5 Activation in Myeloid Malignancies with Specific Clinical and Biologic Correlates. <i>Cancer Cell</i> , 2008, 14, 335-343.	16.8	219
14	Mutations of the NF1 Gene in Children With Juvenile Myelomonocytic Leukemia Without Clinical Evidence of Neurofibromatosis, Type 1. <i>Blood</i> , 1998, 92, 267-272.	1.4	190
15	AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. <i>Cell Stem Cell</i> , 2018, 23, 86-100.e6.	11.1	189
16	Targeting oncogenic Ras signaling in hematologic malignancies. <i>Blood</i> , 2012, 120, 3397-3406.	1.4	171
17	Genetic and Biochemical Evidence That Haploinsufficiency of the <i>Nf1</i> Tumor Suppressor Gene Modulates Melanocyte and Mast Cell Fates in Vivo. <i>Journal of Experimental Medicine</i> , 2000, 191, 181-188.	8.5	168
18	Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. <i>Blood</i> , 2004, 103, 4243-4250.	1.4	162

#	ARTICLE	IF	CITATIONS
19	Disruption of the Mouse Rce1 Gene Results in Defective Ras Processing and Mislocalization of Ras within Cells. <i>Journal of Biological Chemistry</i> , 1999, 274, 8383-8390.	3.4	161
20	p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. <i>Genes and Development</i> , 2010, 24, 1389-1402.	5.9	148
21	KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer. <i>Cell</i> , 2017, 168, 817-829.e15.	28.9	148
22	Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras. <i>Nature</i> , 2009, 461, 411-414.	27.8	141
23	Nf1 Regulates Hematopoietic Progenitor Cell Growth and Ras Signaling in Response to Multiple Cytokines. <i>Journal of Experimental Medicine</i> , 1998, 187, 1893-1902.	8.5	140
24	Functional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells. <i>Blood</i> , 2005, 106, 311-317.	1.4	138
25	Recombinant human erythropoietin in the anemia of prematurity: Results of a placebo-controlled pilot study. <i>Journal of Pediatrics</i> , 1991, 118, 949-955.	1.8	132
26	Nf1 and Gmcsf Interact in Myeloid Leukemogenesis. <i>Molecular Cell</i> , 2000, 5, 189-195.	9.7	132
27	Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. <i>Blood</i> , 2011, 117, 2022-2032.	1.4	132
28	Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. , 1999, 89, 14-22.		119
29	Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. <i>Journal of Clinical Investigation</i> , 2013, 123, 335-339.	8.2	119
30	Circulating Erythroid Progenitors in the Anemia of Prematurity. <i>New England Journal of Medicine</i> , 1987, 317, 728-733.	27.0	117
31	GTPase activating proteins: critical regulators of intracellular signaling. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2002, 1602, 23-45.	7.4	117
32	Deregulated Ras signaling in developmental disorders: new tricks for an old dog. <i>Current Opinion in Genetics and Development</i> , 2007, 17, 15-22.	3.3	109
33	SHP-2 and myeloid malignancies. <i>Current Opinion in Hematology</i> , 2004, 11, 44-50.	2.5	106
34	Inherited predispositions and hyperactive Ras in myeloid leukemogenesis. <i>Pediatric Blood and Cancer</i> , 2006, 46, 579-585.	1.5	103
35	K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. <i>Blood</i> , 2007, 109, 3945-3952.	1.4	103
36	Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness. <i>Nature</i> , 2013, 504, 143-147.	27.8	101

#	ARTICLE	IF	CITATIONS
37	Phase II Study of the Oral MEK Inhibitor Selumetinib in Advanced Acute Myelogenous Leukemia: A University of Chicago Phase II Consortium Trial. <i>Clinical Cancer Research</i> , 2014, 20, 490-498.	7.0	99
38	MLL5, a homolog of <i>Drosophila trithorax</i> located within a segment of chromosome band 7q22 implicated in myeloid leukemia. <i>Oncogene</i> , 2002, 21, 4849-4854.	5.9	92
39	Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells. <i>PLoS Biology</i> , 2009, 7, e1000059.	5.6	89
40	Focus on myeloproliferative diseases and myelodysplastic syndromes. <i>Cancer Cell</i> , 2004, 6, 547-552.	16.8	87
41	Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. <i>Blood</i> , 2011, 117, 4253-4261.	1.4	82
42	In Vitro and In Vivo Effects of a Farnesyltransferase Inhibitor on Nf1-Deficient Hematopoietic Cells. <i>Blood</i> , 1999, 94, 2469-2476.	1.4	81
43	A MEK Inhibitor Abrogates Myeloproliferative Disease in <i>Kras</i> Mutant Mice. <i>Science Translational Medicine</i> , 2011, 3, 76ra27.	12.4	81
44	Biochemical and Functional Characterization of Germ Line <i>KRAS</i> Mutations. <i>Molecular and Cellular Biology</i> , 2007, 27, 7765-7770.	2.3	80
45	Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: A pilot study. <i>Journal of Pediatrics</i> , 1992, 120, 586-592.	1.8	79
46	Juvenile myelomonocytic leukemia: molecular understanding and prospects for therapy. <i>Trends in Molecular Medicine</i> , 1996, 2, 468-475.	2.6	79
47	Preclinical efficacy of MEK inhibition in Nras-mutant AML. <i>Blood</i> , 2014, 124, 3947-3955.	1.4	79
48	The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. <i>Nature Medicine</i> , 2017, 23, 301-313.	30.7	79
49	Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. , 1997, 79, 1438-1446.		78
50	Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies. <i>Blood</i> , 2006, 108, 1684-1689.	1.4	78
51	Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. <i>Cancer Cell</i> , 2018, 34, 852-862.e4.	16.8	73
52	Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. <i>JCI Insight</i> , 2018, 3, .	5.0	71
53	Acute leukemia: A pediatric perspective. <i>Cancer Cell</i> , 2002, 2, 437-445.	16.8	68
54	Resistance in the land of molecular cancer therapeutics. <i>Cancer Cell</i> , 2002, 2, 99-102.	16.8	66

#	ARTICLE	IF	CITATIONS
55	Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. <i>Blood</i> , 2012, 119, 1032-1035.	1.4	66
56	RAS,FLT3, andTP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. <i>Genes Chromosomes and Cancer</i> , 2004, 39, 217-223.	2.8	62
57	Mll5 contributes to hematopoietic stem cell fitness and homeostasis. <i>Blood</i> , 2009, 113, 1455-1463.	1.4	62
58	Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells. <i>Cancer Cell</i> , 2002, 2, 507-514.	16.8	60
59	Mutant <i>Ikzf1</i> , <i>Kras</i> ^{G12D} , and <i>Notch1</i> cooperate in T lineage leukemogenesis and modulate responses to targeted agents. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 5106-5111.	7.1	60
60	Dominant Role of Oncogene Dosage and Absence of Tumor Suppressor Activity in <i>Nras</i> -Driven Hematopoietic Transformation. <i>Cancer Discovery</i> , 2013, 3, 993-1001.	9.4	60
61	Loss of oncogenic <i>Notch1</i> with resistance to a PI3K inhibitor in T-cell leukaemia. <i>Nature</i> , 2014, 513, 512-516.	27.8	60
62	Harnessing preclinical mouse models to inform human clinical cancer trials. <i>Journal of Clinical Investigation</i> , 2006, 116, 847-852.	8.2	59
63	Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. <i>Journal of Experimental Medicine</i> , 2010, 207, 2581-2594.	8.5	58
64	Targeting Ras in Myeloid Leukemias. <i>Clinical Cancer Research</i> , 2008, 14, 2249-2252.	7.0	57
65	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. <i>Blood</i> , 1999, 93, 3617-3623.	1.4	55
66	Biochemical Characterization of a Novel KRAS Insertion Mutation from a Human Leukemia. <i>Journal of Biological Chemistry</i> , 1996, 271, 32491-32494.	3.4	54
67	A retroviral mutagenesis screen reveals strong cooperation between <i>Bcl11a</i> overexpression and loss of the <i>Nf1</i> tumor suppressor gene. <i>Blood</i> , 2009, 113, 1075-1085.	1.4	54
68	Transient monosomy 7. , 1999, 85, 2655-2661.		51
69	Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22. <i>Genomics</i> , 2005, 85, 600-607.	2.9	49
70	Germline Mutations in Components of the Ras Signaling Pathway in Noonan Syndrome and Related Disorders. <i>Cell Cycle</i> , 2006, 5, 1607-1611.	2.6	49
71	ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth. <i>Nature Chemical Biology</i> , 2021, 17, 856-864.	8.0	49
72	Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. <i>Blood</i> , 2000, 96, 2310-2313.	1.4	48

#	ARTICLE	IF	CITATIONS
73	Mutation analysis in Costello syndrome: functional and structural characterization of the <i>HRAS</i> p.Lys117Arg mutation. <i>Human Mutation</i> , 2008, 29, 232-239.	2.5	48
74	Abnormal hematopoiesis in <i>Gab2</i> mutant mice. <i>Blood</i> , 2007, 110, 116-124.	1.4	47
75	Dysregulated <i>RasGRP1</i> Responds to Cytokine Receptor Input in T Cell Leukemogenesis. <i>Science Signaling</i> , 2013, 6, ra21.	3.6	45
76	Candidate Gene Isolation and Comparative Analysis of a Commonly Deleted Segment of 7q22 Implicated in Myeloid Malignancies. <i>Genomics</i> , 2001, 77, 171-180.	2.9	43
77	Therapy-induced malignant neoplasms in <i>Nf1</i> mutant mice. <i>Cancer Cell</i> , 2005, 8, 337-348.	16.8	43
78	Somatic activation of a conditional <i>KrasG12D</i> allele causes ineffective erythropoiesis in vivo. <i>Blood</i> , 2006, 108, 2041-2044.	1.4	41
79	Targeting oncogenic <i>Ras</i> . <i>Genes and Development</i> , 2007, 21, 1989-1992.	5.9	41
80	<i>KRAS</i> Engages <i>AGO2</i> to Enhance Cellular Transformation. <i>Cell Reports</i> , 2016, 14, 1448-1461.	6.4	41
81	Cooperative loss of <i>RAS</i> feedback regulation drives myeloid leukemogenesis. <i>Nature Genetics</i> , 2015, 47, 539-543.	21.4	39
82	Quantitative effects of <i>Nf1</i> inactivation on in vivo hematopoiesis. <i>Journal of Clinical Investigation</i> , 2001, 108, 709-715.	8.2	39
83	Do terminal deletions of 11q23 exist? Identification of undetected translocations with fluorescence in situ hybridization. <i>Genes Chromosomes and Cancer</i> , 1993, 7, 204-208.	2.8	37
84	Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. <i>Journal of Clinical Investigation</i> , 2020, 130, 863-876.	8.2	36
85	<i>Ras</i> processing as a therapeutic target in hematologic malignancies. <i>Current Opinion in Hematology</i> , 2002, 9, 308-315.	2.5	33
86	<i>RAS</i> mutations in pediatric leukemias with <i>MLL</i> gene rearrangements. , 1998, 21, 270-275.		32
87	Genomic structure of the <i>PIK3CG</i> gene on chromosome band 7q22 and evaluation as a candidate myeloid tumor suppressor. <i>Blood</i> , 2002, 99, 372-374.	1.4	32
88	Age-Related Differences in Erythropoietic Response to Recombinant Human Erythropoietin: Comparison in Adult and Infant Rhesus Monkeys. <i>Pediatric Research</i> , 1990, 28, 567-571.	2.3	31
89	JAKing up hematopoietic proliferation. <i>Cancer Cell</i> , 2005, 7, 291-293.	16.8	31
90	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. <i>Neuro-Oncology</i> , 2022, 24, 1845-1856.	1.2	30

#	ARTICLE	IF	CITATIONS
91	Dose-Dependent Effects of Focal Fractionated Irradiation on Secondary Malignant Neoplasms in <i>Nf1</i> Mutant Mice. <i>Cancer Research</i> , 2011, 71, 106-115.	0.9	28
92	The Ras signaling pathway and the molecular basis of myeloid leukemogenesis. <i>Current Opinion in Hematology</i> , 1995, 2, 305-308.	2.5	27
93	De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. <i>Journal of Medical Genetics</i> , 2007, 44, e84-e84.	3.2	27
94	Loss of glucocorticoid receptor expression mediates <i>in vivo</i> dexamethasone resistance in T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2020, 34, 2025-2037.	7.2	27
95	Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia <i>in vivo</i> . <i>Blood</i> , 2013, 121, 4884-4893.	1.4	26
96	Implantation techniques and outcomes after cardiac resynchronization therapy for congenitally corrected transposition of the great arteries. <i>Heart Rhythm</i> , 2018, 15, 1808-1815.	0.7	26
97	\hat{I}^2 common receptor inactivation attenuates myeloproliferative disease in <i>Nf1</i> mutant mice. <i>Blood</i> , 2007, 109, 1687-1691.	1.4	25
98	Molecular evidence that childhood monosomy 7 syndrome is distinct from juvenile chronic myelogenous leukemia and other childhood myeloproliferative disorders. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 50-57.	2.8	24
99	Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignancies. <i>Blood</i> , 2010, 115, 4524-4532.	1.4	24
100	NRAS G12V oncogene facilitates self-renewal in a murine model of acute myelogenous leukemia. <i>Blood</i> , 2014, 124, 3274-3283.	1.4	24
101	Recombinant Human Erythropoietin in Neonatal Anemia. <i>Clinics in Perinatology</i> , 1995, 22, 627-640.	2.1	23
102	Mouse cancer models as a platform for performing preclinical therapeutic trials. <i>Current Opinion in Genetics and Development</i> , 2003, 13, 84-89.	3.3	22
103	A Collaborative Model for Accelerating the Discovery and Translation of Cancer Therapies. <i>Cancer Research</i> , 2017, 77, 5706-5711.	0.9	22
104	Hematologic effects of inactivating the Ras processing enzyme Rce1. <i>Blood</i> , 2003, 101, 2250-2252.	1.4	20
105	Sending out an SOS. <i>Nature Genetics</i> , 2007, 39, 8-9.	21.4	19
106	Catheter Ablation of Ventricular Arrhythmia for Ebstein's Anomaly in Unoperated and Post-Surgical Patients. <i>JACC: Clinical Electrophysiology</i> , 2018, 4, 1300-1307.	3.2	19
107	Genetic disruption of N-RasG12D palmitoylation perturbs hematopoiesis and prevents myeloid transformation in mice. <i>Blood</i> , 2020, 135, 1772-1782.	1.4	18
108	Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis. <i>ELife</i> , 2015, 4, .	6.0	17

#	ARTICLE	IF	CITATIONS
109	Hay in a haystack. <i>Nature</i> , 2008, 451, 252-253.	27.8	16
110	CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition. <i>PLoS ONE</i> , 2019, 14, e0220026.	2.5	16
111	Modeling myeloid leukemia tumor suppressor gene inactivation in the mouse. <i>Seminars in Cancer Biology</i> , 2001, 11, 191-199.	9.6	15
112	IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 11630-11635.	7.1	15
113	KRAS insertion mutations are oncogenic and exhibit distinct functional properties. <i>Nature Communications</i> , 2016, 7, 10647.	12.8	15
114	Role of the NF1 Gene in Leukemogenesis and Myeloid Growth Control. <i>Journal of Pediatric Hematology/Oncology</i> , 1997, 19, 551-554.	0.6	14
115	Leukemic potential of doubly mutant Nf1 and Wv hematopoietic cells. <i>Blood</i> , 2003, 101, 1984-1986.	1.4	14
116	Genetics, Epigenetics, and Leukemia. <i>New England Journal of Medicine</i> , 2010, 363, 2460-2461.	27.0	14
117	Stat5 is critical for the development and maintenance of myeloproliferative neoplasm initiated by Nf1 deficiency. <i>Haematologica</i> , 2016, 101, 1190-1199.	3.5	14
118	Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy. <i>PLoS ONE</i> , 2018, 13, e0193849.	2.5	14
119	Recombinant Erythropoietin in Anemia of Prematurity: Five Years Later. <i>Pediatrics</i> , 1993, 92, 614-617.	2.1	14
120	Molecular analysis at the NF1 locus in astrocytic brain tumors. <i>Cancer</i> , 1995, 76, 674-677.	4.1	12
121	PLC- β 3 and PI3K Link Cytokines to ERK Activation in Hematopoietic Cells with Normal and Oncogenic Kras. <i>Science Signaling</i> , 2013, 6, ra105.	3.6	12
122	Modulation of Ras signaling alters the toxicity of hydroquinone, a benzene metabolite and component of cigarette smoke. <i>BMC Cancer</i> , 2014, 14, 6.	2.6	12
123	Mutations in GATA2 are rare in juvenile myelomonocytic leukemia. <i>Blood</i> , 2014, 123, 1426-1427.	1.4	12
124	KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice. <i>JCI Insight</i> , 2020, 5, .	5.0	10
125	Recombinant Erythropoietin in Pediatrics: A Clinical Perspective. <i>Pediatric Annals</i> , 1990, 19, 197-206.	0.8	10
126	Leukemic Transformation in Patients With Severe Congenital Neutropenia. <i>The American Journal of Pediatric Hematology/Oncology</i> , 2001, 23, 487-495.	1.3	9

#	ARTICLE	IF	CITATIONS
127	High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions. <i>Cell Reports</i> , 2019, 27, 631-647.e5.	6.4	9
128	Granulocyte/macrophage colony-stimulating factor and accessory cells modulate radioprotection by purified hematopoietic cells. <i>Journal of Experimental Medicine</i> , 2005, 201, 853-858.	8.5	8
129	Tumor suppressor gene inactivation in myeloid malignancies. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 601-614.	1.7	8
130	Resistant T-Cell Acute Lymphoblastic Leukemias That Emerge after In Vivo Treatment with Dexamethasone Frequently Down-Regulate Glucocorticoid Receptor Protein Expression. <i>Blood</i> , 2016, 128, 753-753.	1.4	7
131	Myeloid Malignancies Induced by Alkylating Agents in Nf1 Mice. <i>Blood</i> , 1999, 93, 3617-3623.	1.4	6
132	Oncogenic Ras scales the ALPS. <i>Blood</i> , 2011, 117, 2747-2748.	1.4	5
133	A(nother) RAF mutation in LCH. <i>Blood</i> , 2014, 123, 3063-3065.	1.4	5
134	Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias. <i>PLoS Genetics</i> , 2019, 15, e1008168.	3.5	5
135	Myelodysplastic and Myeloproliferative Disorders of Childhood: A Study of 167 Patients. <i>Blood</i> , 1999, 93, 459-466.	1.4	5
136	Acute Myeloid Leukemia Associated With t(8;21) or Trisomy 8 in Children With Neurofibromatosis, Type 1. <i>Journal of Pediatric Hematology/Oncology</i> , 2003, 25, 343.	0.6	4
137	The sum is greater than the FGFR1 partner. <i>Cancer Cell</i> , 2004, 5, 203-204.	16.8	4
138	De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. <i>BMJ Case Reports</i> , 2009, 2009, bcr0720080550-bcr0720080550.	0.5	4
139	Mechanistic and Preclinical Insights from Mouse Models of Hematologic Cancer Characterized by Hyperactive Ras. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a031526.	6.2	3
140	<i>Nf1</i>-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 2382-2395.	4.1	3
141	Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. <i>Cancer</i> , 1997, 79, 1438-1446.	4.1	3
142	Combination of a MEK Inhibitor, AZD6244, and Dual PI3K/mTOR Inhibitor, NVP-BEZ235: An Effective Therapeutic Strategy for Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 3978-3978.	1.4	3
143	Advancing the STATus of MPN pathogenesis. <i>Blood</i> , 2012, 119, 3374-3376.	1.4	2
144	Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. <i>American Journal of Medical Genetics Part A</i> , 1999, 89, 14-22.	2.4	2

#	ARTICLE	IF	CITATIONS
145	Germline Mutations in CBL Cause a Predisposition to Juvenile Myelomonocytic Leukemia.. Blood, 2009, 114, 310-310.	1.4	2
146	Evidence that juvenile myelomonocytic leukemia can arise from a pluripotential stem cell. Blood, 2000, 96, 2310-2313.	1.4	2
147	Chemical proteomic analysis of palmostatin beta-lactone analogs that affect N-Ras palmitoylation. Bioorganic and Medicinal Chemistry Letters, 2021, 53, 128414.	2.2	2
148	Heritable predispositions to childhood hematologic malignancies. , 0, , 362-388.		2
149	Rationale for Using Recombinant Human Erythropoietin to Treat the Anemia of Prematurity. Contributions To Nephrology, 1989, 76, 324-329.	1.1	1
150	Genetic Predispositions and Childhood Cancer. Environmental Health Perspectives, 1998, 106, 801.	6.0	1
151	Reconsidering how we treat severe congenital neutropenia. Blood, 2006, 107, 4575-4576.	1.4	1
152	More than kin and less than kind. Nature, 2009, 460, 805-807.	27.8	1
153	Soil and Seed: Coconspirators in Therapy-Induced Myeloid Neoplasms. Blood Cancer Discovery, 2020, 1, 10-12.	5.0	1
154	NF1 Mutations in Hematologic Cancers. , 2012, , 469-485.		1
155	Treatment with a MEK Inhibitor Improves Myeloproliferation, Anemia and Survival in a Mouse Model of CMML and JMML.. Blood, 2009, 114, 966-966.	1.4	1
156	Kras G12D Expression in Hematopoietic Stem/Progenitor Cells Initiates T Cell Acute Lymphoblastic Leukemia/Lymphoma.. Blood, 2007, 110, 153-153.	1.4	1
157	The PI3K Inhibitor GDC-0941 Attenuates Disease in a KrasG12D Mouse Model of CMML and JMML.. Blood, 2012, 120, 2862-2862.	1.4	1
158	A "Ras-in-ALL" model of signaling?. Blood, 2004, 104, 297-298.	1.4	0
159	The SPS Affair: A Complex Tale of Illicit Proliferation. Cancer Cell, 2009, 16, 87-88.	16.8	0
160	Genetic Dissection of Cooperating Mutations in BXH-2 Acute Myeloid Leukemia with and without Nf1 Gene Mutation.. Blood, 2004, 104, 2567-2567.	1.4	0
161	Novel Germ Line Mutations in the KRAS2 Gene Cause Noonan Syndrome and Deregulate Hematopoietic Cell Growth.. Blood, 2005, 106, 1602-1602.	1.4	0
162	Intracellular Signals as Molecular Biomarkers for Therapeutic Responses in Kras Mutant Myeloid Cells.. Blood, 2007, 110, 2196-2196.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Bcl11a Causes p21Cip1 Down-Regulation and Transplantable Leukemia in Nf1-Deficient Mice.. Blood, 2007, 110, 2657-2657.	1.4	0
164	Leukemogenic K-RasG12D Induces Cell Cycle Entry and Clonal Dominance in Hematopoietic Stem Cells.. Blood, 2007, 110, 778-778.	1.4	0
165	PI3 Kinase, Phospholipase C (PLC)- β 3, and RasGRPs Act Cooperatively to Activate the Ras-Extracellular-Related Kinase (ERK) Pathway in Response to Cytokines in Normal and Kras Mutant Myeloid Cells.. Blood, 2009, 114, 2512-2512.	1.4	0
166	Oncogene Withdrawal Selectively Alters Phosphoprotein States and Shifts Differentiation Status In Myeloid Leukemia Subpopulations. Blood, 2010, 116, 3160-3160.	1.4	0
167	Akt Activation Is Important In KRAS-Mediated Multistep Leukemogenesis. Blood, 2010, 116, 4200-4200.	1.4	0
168	Heterozygous Germ Line Deletion of a 2Mb Interval in Mice That Models Loss of 7q22 in Human Myeloid Malignancies Results in Defective Hematopoietic Stem Cell Function Reminiscent of Premature Aging. Blood, 2011, 118, 2340-2340.	1.4	0
169	Delineating Critical Effectors of Remission Induction in a Mouse Model of AML. Blood, 2011, 118, 5232-5232.	1.4	0
170	Mechanisms of Relapse Following Targeted Therapy in An NRASG12V and Mll-AF9 Driven Mouse Model of AML. Blood, 2011, 118, 2620-2620.	1.4	0
171	Activated NRAS Mediates Self-Renewal Capacity in AML by Facilitating the Mll/AF9-Specified Gene Expression Signature. Blood, 2012, 120, 5116-5116.	1.4	0
172	Oncogenic Nras Increases Hematopoietic Stem Cell Proliferation and Self-Renewal Through a Bimodal Effect. Blood, 2012, 120, 119-119.	1.4	0
173	Identification of CKMT1B As a New Target in EVI1-Positive AML. Blood, 2015, 126, 3674-3674.	1.4	0
174	Targeting the Creatine Kinase Pathway in EVI1-Positive Acute Myeloid Leukemia. Blood, 2016, 128, 523-523.	1.4	0
175	Response and Resistance to Bromodomain Inhibition in AML Driven By Hyperactive Ras Signaling. Blood, 2016, 128, 1654-1654.	1.4	0
176	Glucocorticoids Paradoxically Induce Intrinsic Steroid Resistance through a STAT5-Mediated Survival Mechanism in T-Cell Acute Lymphoblastic Leukemia. Blood, 2018, 132, 913-913.	1.4	0
177	Co-Targeting BET Bromodomain Proteins and Aberrant Signaling in AML. Blood, 2020, 136, 5-6.	1.4	0